CL2023000194A1 - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents
Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-iloInfo
- Publication number
- CL2023000194A1 CL2023000194A1 CL2023000194A CL2023000194A CL2023000194A1 CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1 CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- oxadiazol
- formulation
- methyl
- low dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable de este, en donde el compuesto de Fórmula I, o una sal farmacéuticamente aceptable de este, se administra por vía oral con una dosis total del compuesto de 0,1 mg/día a 5 mg/día, y es útil para tratar una enfermedad neurodegenerativa, incluidas las tauopatías neurodegenerativas, como la enfermedad de Alzheimer, la demencia frontotemporal, el síndrome corticobasilar y la parálisis supranuclear progresiva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000194A1 true CL2023000194A1 (es) | 2023-07-21 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000194A CL2023000194A1 (es) | 2020-07-23 | 2023-01-19 | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (es) |
| EP (1) | EP4185291A1 (es) |
| JP (1) | JP2023535034A (es) |
| KR (1) | KR20230043905A (es) |
| CN (1) | CN116323604A (es) |
| AR (1) | AR123031A1 (es) |
| AU (1) | AU2021312894A1 (es) |
| BR (1) | BR112023000975A2 (es) |
| CA (1) | CA3186808A1 (es) |
| CL (1) | CL2023000194A1 (es) |
| CO (1) | CO2023000594A2 (es) |
| DO (1) | DOP2023000009A (es) |
| EC (1) | ECSP23005057A (es) |
| IL (1) | IL300023A (es) |
| MX (1) | MX2023000993A (es) |
| PE (1) | PE20231031A1 (es) |
| TW (1) | TW202220650A (es) |
| WO (1) | WO2022020663A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110747A1 (es) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
| JP2021530552A (ja) * | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894A1/en active Pending
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291A1/en active Pending
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en active Application Filing
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000975A2 (pt) | 2023-02-07 |
| CO2023000594A2 (es) | 2023-01-26 |
| AU2021312894A1 (en) | 2023-02-23 |
| AR123031A1 (es) | 2022-10-26 |
| DOP2023000009A (es) | 2023-02-15 |
| KR20230043905A (ko) | 2023-03-31 |
| EP4185291A1 (en) | 2023-05-31 |
| WO2022020663A1 (en) | 2022-01-27 |
| CA3186808A1 (en) | 2022-01-27 |
| MX2023000993A (es) | 2023-03-01 |
| JP2023535034A (ja) | 2023-08-15 |
| ECSP23005057A (es) | 2023-02-28 |
| PE20231031A1 (es) | 2023-07-10 |
| CN116323604A (zh) | 2023-06-23 |
| TW202220650A (zh) | 2022-06-01 |
| IL300023A (en) | 2023-03-01 |
| US20230338349A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CL2021001288A1 (es) | Heterociclos funcionalizados como agentes antivirales | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| CL2023000194A1 (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| RU2014147728A (ru) | Производное транс-2-деценовой кислоты и содержащее его лекарственное средство | |
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| EA202193266A1 (ru) | Антибактериальные производные аминогликозидов | |
| UY39649A (es) | Compuesto para el tratamiento de trastornos cognitivos | |
| ECSP24006915A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
| AR121671A1 (es) | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el ácido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxílico o una sal farmacéutica del mismo |